TIDMPRTC
RNS Number : 2951N
PureTech Health PLC
29 January 2021
29 January 2021
PureTech Health plc
PureTech Adds Bharatt Chowrira, PureTech's President and Chief
of Business and Strategy, to Board of Directors
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announces the appointment
of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an
executive director. Dr. Chowrira has served as PureTech's President
and Chief of Business and Strategy since March 2017 and will
continue in that role as an executive director of the Company. Dr.
Chowrira's appointment is effective from February 1, 2021.
"Bharatt has made a big impact since joining PureTech in 2017
and he continues to make key contributions as we advance our
clinical pipeline toward key value-driving milestones," said Daphne
Zohar, Founder and Chief Executive Officer of PureTech Health, "We
are pleased to have him join our board of directors as one of the
three representatives of our executive team."
As the President and Chief of Business and Strategy at PureTech,
Dr. Chowrira oversees the Company's strategy and business
development initiatives.
"PureTech is making remarkable progress in the clinic as we
pioneer potentially transformational therapies for patients with
devastating diseases," said Dr. Chowrira. "I'm pleased to join the
distinguished members of our Board as we aim to fulfill our vision
of giving life to science through innovative solutions to serious
public health challenges."
Dr. Chowrira has more than two decades of experience in the
biopharma industry, combining a unique blend of R&D, business
development, operations, financing and legal expertise. Prior to
joining PureTech, Dr. Chowrira was the president of Synlogic, Inc.,
a biopharmaceutical company focused on developing synthetic
microbiome-based therapeutics, from September 2015 to February
2017, where he oversaw and managed corporate and business
development, alliance management, financial, human resources,
intellectual property and legal operations. Prior to joining
Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex
Pharmaceuticals Inc., from 2013 to 2015, which was acquired by Teva
Pharmaceuticals in the Spring of 2015. Prior to that, Dr. Chowrira
held various leadership and management positions, including at
Nektar Therapeutics (Chief Operating Officer), Merck & Co, or
Merck (Vice President), Sirna Therapeutics (General Counsel;
acquired by Merck) and Ribozyme Pharmaceuticals (Chief Patent
Counsel). Dr. Chowrira has been involved in the boards of several
of PureTech's Founded Entities. He is currently a member of the
Board of Directors of Vedanta Biosciences, Inc., and he was
previously on the boards of Vor Biopharma, Inc. and Karuna
Therapeutics, Inc. (Nasdaq: KRTX). Dr. Chowrira received a JD from
the University of Denver's Sturm College of Law, a PhD in molecular
biology from the University of Vermont College of Medicine, an MS
in molecular biology from Illinois State University and a BS in
microbiology from the UAS, Bangalore, India.
The company confirms that there is no further information
required to be disclosed pursuant to paragraph 9.6.13 of the UK
Listing Rules.
PureTech's Board of Directors
PureTech's Board of Directors include former executives of major
pharmaceutical companies, entrepreneurs, and award winning academic
and clinical leaders who leverage their expertise to support our
mission. Following the appointment of Dr Chowrira, the board of
directors is comprised of the following members:
Daphne Zohar, Founder, Chief Executive Officer and Director -
Daphne Zohar is the Founder and Chief Executive Officer of
PureTech, and she has served as a member of PureTech's Board of
Directors since the Company's founding. She has also served as the
founding Chief Executive Officer of a number of PureTech's Founded
Entities. A successful entrepreneur, Ms. Zohar created PureTech,
assembling a leading team to help implement her vision for the
Company, and was a key participant in fundraising, business
development and establishing the underlying programs and platforms
that have resulted in PureTech's substantial pipeline.
Chris Viehbacher, Board Chairman - Chris Viehbacher has served
as a member of PureTech's Board of Directors since 2015 and as
Chairman since September 2019. He is the Managing Partner of Gurnet
Point Capital, a Boston based investment fund associated with the
Bertarelli family and has a $2 billion capital allocation. He is
the former CEO and member of the Board of Directors of Sanofi and
was also the Chairman of the Board of Genzyme in Boston.
Bharatt Chowrira, PhD, JD, President, Chief of Business and
Strategy and Director - Bharatt Chowrira, PhD, JD, is the President
and Chief of Business and Strategy of PureTech, and he has served
as a member of PureTech's Board of Director's since 2021. Prior to
joining PureTech, Dr. Chowrira was the President of Synlogic, Inc.
He previously served as the Chief Operating Officer of Auspex
Pharmaceuticals Inc., until its acquisition by Teva
Pharmaceuticals, and he has held various leadership and management
positions across the biopharmaceutical industry.
Raju Kucherlapati, PhD, Independent Non-Executive Director -
Raju Kucherlapati, PhD, has served as a member of PureTech's Board
of Directors since 2014. He is the Paul C. Cabot Professor of
Genetics and Professor of Medicine at Harvard Medical School. Dr.
Kucherlapati was a founder and formerly a board member of Abgenix
(acquired by Amgen for $2.2 billion), Cell Genesys and Millennium
Pharmaceuticals (acquired by Takeda for $8.8 billion).
John LaMattina, PhD, Independent Non-Executive Director - John
LaMattina, PhD, has served as a member of PureTech's Board of
Directors since 2009. Dr. LaMattina was previously president of
Pfizer Global Research and Development and held positions of
increasing responsibility during his 30-year career at Pfizer.
Bob Langer, ScD, Co-Founder and Non-Executive Director - Bob
Langer, ScD, is a Co-founder of PureTech and has served as a member
of PureTech's Board of Directors since the Company's founding. He
has served as the David H. Koch Institute Professor at MIT since
2005. He is one of 12 institute professors, which is the highest
honor that can be awarded to a faculty member at MIT. Dr. Langer
has received over 220 major awards and is the most cited engineer
in history.
Kiran Mazumdar-Shaw, Independent Non-Executive Director - Kiran
Mazumdar-Shaw has served as a member of PureTech's Board of
Directors since 2020. She is a pioneering biotech entrepreneur, a
healthcare visionary, a global influencer and a passionate
philanthropist. She is a pioneer of India's biotech industry and
founder of Biocon.
Stephen M Muniz, Esq., Co-Founder, Chief Operating Officer and
Director - Stephen Muniz, Esq., is a Co-founder and the Chief
Operating Officer of PureTech, and he has served as a member of
PureTech's Board of Directors since 2015. Prior to joining
PureTech, Mr. Muniz was a Partner in the Corporate Department of
Locke Lord LLP, where he focused on the representation of life
science venture funds as well as their portfolio companies in
general corporate matters and in investment and liquidity
transactions.
Dame Marjorie Scardino, Senior Independent Director - Dame
Marjorie Scardino has served as a member of PureTech's Board of
Directors since 2015. She served as Chief Executive of The
Economist for 12 years and was the Chief Executive of Pearson plc,
the world's leading education company and the owner of Penguin
Books and The Financial Times Group. She served as chairman of The
MacArthur Foundation from 2012 to 2017, and later became the
Chairman of the London School of Hygiene and Tropical Medicine.
PureTech's R&D Committee
PureTech's R&D Committee works in close collaboration with
the board and PureTech's network of scientific experts to drive our
distinctive R&D model for advancing scientific breakthroughs.
The Committee is comprised of board members Bob Langer, ScD, Raju
Kucherlapati, PhD, and John LaMattina, PhD, in addition to the
following members:
H. Robert Horvitz, PhD, Board Observer and R&D Committee
Chair - H. Robert Horvitz, PhD, is a Board Observer and Chair of
PureTech's R&D Committee. He received the Nobel Prize in
Physiology or Medicine and is the David H Koch Professor of Biology
at Massachusetts Institute of Technology, an investigator of the
Howard Hughes Medical Institute, neurobiologist (neurology) at
Massachusetts General Hospital, a member of the MIT McGovern
Institute for Brain Research and the MIT Koch Institute for
Integrative Cancer Research. He is cofounder of multiple life
science companies, including Epizyme (EPZM), Mitobridge (acquired
by Astellas) and Idun Pharmaceuticals (acquired by Pfizer) and was
a member of the Scientific Advisor Board of the Novartis Institutes
for BioMedical Research.
Dennis Ausiello, MD, R&D Committee Member - Dennis Ausiello,
MD, is a member of PureTech's R&D Committee. He is the Jackson
Distinguished Professor of Clinical Medicine and was previously
Director, Emeritus of the MD/PhD Program at Harvard Medical School.
Dr. Ausiello is Chairman of Medicine, Emeritus and Director of the
Center for Assessment Technology and Continuous Health (CATCH) at
Massachusetts General Hospital (MGH). Dr. Ausiello served on the
Board of Directors of Pfizer Pharmaceuticals, where he was their
former Lead Director.
Bennett Shapiro, MD, Co-founder and R&D Committee Member -
Ben Shapiro, MD, is a Co-founder and member of PureTech's R&D
Committee. As former Executive Vice President at Merck Research
Laboratories of Merck & Co., Dr. Shapiro initially led
Worldwide Basic Research and was responsible for all the basic and
preclinical research activities at Merck. He later led Worldwide
Licensing and External Research and was responsible for Merck's
relationships with the academic and industrial biomedical research
community. His leadership resulted in the discovery, development
and registration of approximately 25 drugs and vaccines.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our product candidates, our expectations regarding the
appointment of Bharatt Chowrira to the Board of Directors and those
risks and uncertainties described in the risk factors included in
the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting. stephanie@tenbridgecommunications.
com com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABPMJTMTJTTRB
(END) Dow Jones Newswires
January 29, 2021 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024